Eli Lilly and Company (NYSE:LLY) Shares Acquired by Columbia Trust Co 01012016

Columbia Trust Co 01012016 increased its position in Eli Lilly and Company (NYSE:LLY) by 3.8% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,056 shares of the company’s stock after acquiring an additional 39 shares during the period. Columbia Trust Co 01012016’s holdings in Eli Lilly and Company were worth $616,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of LLY. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company during the third quarter worth approximately $27,000. Retirement Group LLC increased its position in shares of Eli Lilly and Company by 159.1% in the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after acquiring an additional 35 shares in the last quarter. Cornerstone Planning Group LLC acquired a new stake in shares of Eli Lilly and Company in the second quarter worth $33,000. Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company in the third quarter worth $35,000. Finally, Optiver Holding B.V. acquired a new stake in shares of Eli Lilly and Company in the third quarter worth $36,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $2.05 during trading hours on Tuesday, reaching $775.19. The company’s stock had a trading volume of 2,098,618 shares, compared to its average volume of 3,252,679. The company’s 50 day simple moving average is $725.15 and its 200 day simple moving average is $634.68. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a one year low of $323.26 and a one year high of $800.78. The stock has a market cap of $736.55 billion, a P/E ratio of 133.65, a price-to-earnings-growth ratio of 1.69 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period last year, the firm posted $2.09 EPS. The company’s revenue for the quarter was up 28.1% on a year-over-year basis. As a group, analysts expect that Eli Lilly and Company will post 12.42 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 195,055 shares of company stock valued at $125,254,657 in the last quarter. Company insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of several recent research reports. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Barclays increased their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price for the company. in a research note on Wednesday, February 21st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, February 20th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $689.52.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.